Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

计划入组 32 人 · 首次发布于 2024 年 10 月 26 日

Single Ascending Doses of HER-096 in Healthy Subjects

计划入组 60 人 · 首次发布于 2023 年 6 月 22 日

GAGE Act With Her-Ethiopia Evaluation

计划入组 4,500 人 · 首次发布于 2019 年 3 月 26 日

HER-102

HER-902

HER-096

BREW BLUE TEA PTY LTD.

Australia

Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie

Netherlands

Per Humpert

Germany

CHFA Names Eight Emerging Canadian Wellness Brands as Finalists for 2026 Launch Pad Competition

HER-Vaxx Plus Chemotherapy Shows Survival Benefit in HER2-Overexpressing Gastric Cancer

Brazil-India Partnership Advances Pertuzumab Development for HER-2 Metastatic Breast Cancer